Electronic cigarettes versus nicotine-replacement therapy for smoking cessation: A systematic review and meta-analysis of randomized controlled trials

Jing Li1,2, Xu Hui1,2, Jiani Fu3, Muhammad Muneeb Ahmed4, Liang Yao5, Kehu Yang1,2,6

ABSTRACT

INTRODUCTION Nicotine-replacement therapy (NRT) and electronic cigarettes (e-cigarettes) have been frequently used for smoking cessation. The aim of this review is to investigate the effectiveness and safety of e-cigarettes versus NRT for smoking cessation.

METHODS We searched PubMed, EMBASE, the Cochrane Library from inception to 10 October 2021. We included randomized controlled trials (RCTs) comparing e-cigarettes versus NRT for smoking cessation. Two authors independently screened titles, abstracts and full texts for eligibility. Paired authors extracted data, assessed risk of bias, and used GRADE (Grades of Recommendation, Assessment, Development, and Evaluation) to rate the certainty of evidence.

RESULTS The study included five RCTs with 1748 participants. The meta-analysis suggested the e-cigarettes versus NRT increased the ≥6 months continuous abstinence rate (RR=1.67; 95% CI: 1.21–2.28; 55 more per 1000 participants, low certainty), and 7-day point abstinence rate at ≥6 months follow-up (RR=1.43; 95% CI: 1.19–1.72; 84 more per 1000, low certainty). However, we found no evidence that e-cigarettes versus NRT increased 3–6 months continuous abstinence rate (RR=1.07; 95% CI: 0.73–1.57; 10 more per 1000, very low certainty) and <3 months continuous abstinence rate (RR=1.20; 95% CI: 0.90–1.60; 54 more per 1000, low certainty); similar results were found at <3 months follow-up (RR=1.19; 95% CI: 0.92–1.54; 55 more per 1000, very low certainty) and 3–6 months follow-up in 7-day point abstinence rate (RR=1.01; 95% CI: 0.70–1.44; 2 more per 1000, very low certainty). The adverse events were not significant between e-cigarettes and NRT other than throat irritation (RR=1.27; 95% CI: 1.13–1.42; 118 more per 1000, low certainty).

CONCLUSIONS E-cigarettes appeared to be superior to NRT in ≥6 months continuous abstinence rate and 7-day point abstinence rate. At short-term duration, we found no evidence that e-cigarettes compared to NRT increased the <6 months continuous abstinence rate and 7-day point abstinence rate.

INTRODUCTION

The tobacco epidemic is one of the biggest public health threats the world has ever faced, an estimated 1.3 billion people worldwide use tobacco products, killing more than 8 million people a year around the world1. Quitting smoking is beneficial to health at any age; further, quitting smoking before the age of 40 years
reduces the risk of death associated with continued smoking by about 90%\textsuperscript{2,3}.

Nicotine-replacement therapy (NRT) including nicotine gum, patch, lozenges, sprays, and inhalers) and electronic cigarettes (e-cigarettes) have been used for decades in many countries for aiding smoking cessations\textsuperscript{4-7}. Because of the poor compliance, the NRT are usually combined with behavioral support to quit smoking\textsuperscript{8,9}. Compared with NRT, e-cigarettes received higher satisfaction ratings in smokers, due to the various flavors and popular shapes\textsuperscript{10-12}. However, researchers found that e-cigarettes could increase the risk of short-term adverse events including mouth and throat irritation, dry cough, and nausea\textsuperscript{13,14}, as well as the risk of long-term adverse events including asthma and COPD\textsuperscript{12,14-16}, brain damage\textsuperscript{17}, miscarriage, and abnormal brain development\textsuperscript{18,19}.

Moreover, the effectiveness of e-cigarettes and NRT remains inconsistent; epidemiological studies showed that the smoking cessation in e-cigarettes users was 1.6–3.2 times higher than in NRT users\textsuperscript{20-22}. While the randomized control trials (RCTs) evidence suggests conflicting results\textsuperscript{23-25}. Although a current Cochrane review addressed e-cigarettes and NRT, the review did not conduct adequate subgroup analysis based on different duration of continuous abstinence rate, and did not include 7-day point abstinence rate in their analysis\textsuperscript{26}. Therefore, we designed this comprehensive systematic review and meta-analysis to explore the different follow-up duration of smoking cessation rate between e-cigarettes and NRT.

METHODS

Search strategy
We performed a systematic review and meta-analysis of RCTs using a predefined protocol as per the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) recommendations\textsuperscript{27-29} (Supplementary file). Our study was registered in PROSPERO (CRD42020161815). We searched PubMed, Embase, and the Cochrane Library from inception to 10 October 2021. The computer-based searches combined search terms related to the intervention (e.g. electronic nicotine delivery systems, electronic cigarette, vaping, and e-cig) and control (e.g. nicotine-replacement therapy, NRT, nicotine patch, and nicotine gum) in humans, without language and publication year restrictions. The search strategy and specific terms used are listed in the Supplementary file. Two authors (XH and JL) independently screened titles and abstracts of all initially identified studies according to the selection criteria. Full-text articles of studies meeting the selection criteria were retrieved by two reviewers (JL and JNF), independently. Disagreements between evaluators were resolved by discussions with a third person.

Selection criteria
We included RCTs assessing the smoking cessation of e-cigarettes and NRT in adults aged ≥18 years. We excluded non-randomized, observational studies, abstract, poster, letter, and other types of studies that did not undergo peer review. The patient important outcomes included continuous abstinence rate at <3 months, 3–6 months and ≥6 months, 7-day point prevalence of abstinence (the percentage of former smokers who are not smoking at a 7-day point in time\textsuperscript{30}), and adverse events.

Data extraction and quality assessment
Two authors (JL and JNF) extracted data, independently. In case of inconsistency, consensus was reached by discussions. A standardized predesigned data extraction form was used to obtain the relevant data from each study, including general information (e.g. country, study design, follow-up duration etc.), study participants (e.g. sample size, age, gender etc.), intervention description and outcomes of interest (e.g. continuous abstinence rate, 7-day point prevalence of abstinence, adverse events).

Potential sources of bias in RCTs were assessed using the Cochrane Collaboration’s risk of bias tool, which assesses the following 7 possible sources of bias: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other bias\textsuperscript{31}. For each domain, studies were classified as low, unclear, or high risk of bias\textsuperscript{32}.

The GRADE (Grades of Recommendation, Assessment, Development, and Evaluation) system was used to evaluate the certainty of the underlying evidence\textsuperscript{33}. The system classified certainty of evidence as high, moderate, low, or very low according to factors that might downgrade the certainty: risk of bias, inconsistency, imprecision, indirectness and publication bias\textsuperscript{34,35}. 

Tob. Induc. Dis. 2022;20(October):90
https://doi.org/10.18332/tid/154075
Statistical analysis
Binary outcomes were presented as relative risk (RR) with 95% confidence interval (CI). The overall effect was pooled using random-effects model. Statistical heterogeneity among studies were measured by the I^2 statistic and Q test, with I^2>50% and p<0.05 indicating moderate heterogeneity, and I^2>75% and p<0.05 indicating high heterogeneity. We conducted a subgroup analysis according to short-term (<3 months), medium-term (3–6 months) and long-term follow-up (≥6 months) to explore the subgroup modifications. Unfortunately, given that the review involved fewer than 10 studies, we did not explore potential publication bias using a funnel plot and Egger intercept. We used Review Manager 5.3 software to perform the meta-analysis.

RESULTS
Study selection
Figure 1 shows how we identified relevant randomized controlled trials. A total of 2148 articles were retrieved from the databases and relevant bibliographies. We excluded 392 duplicate articles and an additional 1712 articles that did not fulfill the selection criteria. After reviewing the full texts of the remaining 44 articles, we included 5 RCTs in the final analyses (Figure 1).

Study characteristics
The characteristics of the included trials are presented in Table 1. The five eligible trials consist of a total of 1748 participants (872 in e-cigarettes group and 876 in NRT group), of whom, 67% were male, and the median age was 42 years. The NRT therapy was varied among studies: including nicotine patches in two studies, nicotine gum in one study, and nicotine-replacement products in two studies. One study was conducted in the US, one each in Korea, New Zealand, UK, and Australia.

The longest follow-up duration of ≥6 months was in three trials, <6 months in two trials. After treatment, 29–80% of the patients still used e-cigarettes.

Risk of bias
All the included studies had a low risk of bias in random sequence generation and selective reporting. Four trials were rated as low risk of bias and another one was rated as high risk in allocation concealment domain. Four trials were rated as high risk of bias and one was rated as unclear risk in performance bias. In the detection bias domain, two trials were rated as high risk of bias and one was rated as low risk. Four trials were rated as high risk of bias and one was rated as low risk in attrition bias domain (Figure 2 and Supplementary file Figure S1).

Continuous abstinence rate
Figure 3 presents continuous abstinence rate outcomes. Both e-cigarettes and NRT could help increase smoking cessation rate at ≥6 months (14% vs 8%), 3–6 months (17% vs 15%), and at <3 months (36% vs 27%). The meta-analysis results suggest that e-cigarettes versus NRT was associated with higher continuous smoking cessation rate at ≥6 months (RR=1.67; 95% CI: 1.21–2.28; 55 more per 1000; low certainty). However, the continuous abstinence rate of e-cigarettes was not statistically significant at <3 months (RR=1.20; 95% CI: 0.90–1.60; 54 more per 1000, low certainty) and 3–6 months follow-up duration (RR=1.07; 95% CI: 0.73–1.57; 10 more per 1000, very low certainty) (Table 2 and Figure 3).

7-day point abstinence rate
Five studies reported the 7-day point abstinence rate. The meta-analysis suggested that compared with NRT, e-cigarettes increased 7-day point abstinence rate at ≥6 months follow-up (28% vs 20%; RR=1.43; 95% CI: 1.19–1.72; 84 more per 1000, low certainty), but the benefits of e-cigarettes with regard to 7-day point abstinence rate were not statistically significant at 3–6 months follow-up (22% vs 21%; RR=1.01; 95% CI: 0.70–1.44; 2 more per 1000, very low certainty) and at <3 months (38% vs 29%; RR=1.19; 95% CI: 0.92–1.54; 55 more per 1000, very low certainty) (Figure 4).

Adverse events
We did not observe that the e-cigarettes group and NRT group differed in any adverse events (50% vs 41%; RR=1.20; 95% CI: 0.97–1.48; 82 more per 1000, very low certainty), serious adverse events such as pneumonia, acute myocardial infarction and asthmatic attack (7% vs 8%; RR=1.29; 95% CI: 0.73–2.28; 24 more per 1000, very low certainty), cough (26% vs 32%; RR=0.98; 95% CI: 0.48–2.00; 6 fewer per 1000, very low certainty), nausea (27% vs 34%; RR=0.70;
### Table 1. Characteristics of the included studies

| Author Year | Country       | Follow-up duration (months) | Total n | Intervention n | Control n | Participants | Products | Multi-center | Primary outcome | Secondary outcome | Definition of smoking cessation |
|-------------|---------------|-----------------------------|---------|----------------|-----------|--------------|----------|--------------|----------------|-----------------|--------------------------------|
| Bullen24, 2014¶¶, ¶ | New Zealand | 6                           | 584     | 289            | 295       | 42.0 | 224 (38.36) | 25.90 | 128 (21.9) | e-cigarettes nicotine patches No | 21/289 17/295 29% | Any adverse event (37) Serious adverse event*(7) | A: self-reported abstinence over the whole follow-up period, allowing ≤5 cigarettes in total; B: proportion reporting no smoking of tobacco cigarettes, not a puff, in the past 7 days. |
| Lee25, 2018† | USA           | 4.5                         | 30      | 20             | 10        | 53.7 | 27 (90.00) | 32.0 | 6 (20.0)   | e-cigarettes nicotine patches No | 5/20 1/10 80% | Any adverse event (50) Serious adverse event (0); throat irritation (25); cough (40); nausea (25); headache (20) | NR |
| Hajek38, 2019¶¶, ¶ | UK           | 12                          | 884     | 438            | 446       | 460 (52.04) | 41.0 | 188 (21.3) | e-cigarettes nicotine-replacement products Yes (3) | 79/438 44/446 80% | Any adverse event (65) Serious adverse event** (13); throat irritation (65); cough (31); nausea (31) | A: self-report of smoking no more than five cigarettes from 2 weeks after the target quit date, validated biochemically by an expired carbon monoxide level of <8 ppm at 1 year follow-up and not contradicted by any previous self-report or validation result; B: NR. |

Continued
| Author Year | Country | Follow-up duration (months) | Total | Intervention | Control | Male (years) | Smoked (years) mean (SD) | Lost to follow-up (%) |
|-------------|---------|----------------------------|-------|--------------|---------|--------------|--------------------------|-----------------------|
| Lee23 2019  | Korea   | 3                          | 150   | 75           | 75      | 42.3 (100)   | 23.26 (7.60)             | 18 (12.0)             |
|             |         |                            |       | Intervention | Control |              |                          |                       |
|             |         |                            |       | e-cigarettes | nicotine gum | No            | 16/75                   | 21/75 NR               |
|             |         |                            |       |             |         |              | Adverse event (7)       | Adverse event (0)     |
|             |         |                            |       |             |         |              | Serious adverse event (0); | Serious adverse event (0); |
|             |         |                            |       |             |         |              | throat irritation (0);   | throat irritation (0); |
|             |         |                            |       |             |         |              | cough (4); nausea (1);   | cough (4); nausea (1); |
|             |         |                            |       |             |         |              | headache (1)             | headache (1)           |
| Bonevski39  | Australia | 6                          | 100   | 50           | 50      | 40.9 (67.00) | NR                      | 50 (50)               |
|             |         |                            |       | Intervention | Control |              | Adverse event (60)       | Adverse event (40)    |
|             |         |                            |       | nicotine vaping products | nicotine-replacement products | No            | 9/25 10/25 | 48%       | 7/25 9/25 | A: self-report of smoking ≤5 cigarettes since the date. B: proportion reporting no smoking of tobacco cigarettes, not a puff, in the past 7 days |

CAR: continuous abstinence rate. *Serious adverse event by convention includes death, life-threatening illness, admission to hospital or prolongation of hospital stay, persistent or significant disability or incapacity, congenital abnormality, medically important. **Pneumonia, acute myocardial infarction, depression etc. ¶¶ We defined the follow-up duration as time after the intervention to the end of follow-up. ¶¶ Studies reported secondary outcomes of treatment adherence, relapse rate. ¶ Study reported acceptability or satisfaction of product. A: continuous abstinence rate. B: 7-day point abstinence rate.
95% CI: 0.21–2.35; 101 fewer per 1000, very low certainty) and headache (5% vs 7%; RR=0.50; 95% CI: 0.18–1.42; 35 fewer per 1000, very low certainty), one exception for throat irritation (55% vs 44%; RR=1.27; 95% CI: 1.13–1.42; 118 more per 1000, low certainty) (Table 2 and Figure 5). 

**Publication bias**

Publication bias was not assessed since we included fewer than 10 studies.
Figure 2. Summary of risk of bias for each trial

- Green: low risk of bias
- Red: high risk of bias
- Yellow: unclear risk of bias

Figure 3. Subgroup analyses by follow-up duration in continuous abstinence rate in participants receiving e-cigarettes versus NRT

| Study or Subgroup | E-cigarettes | NRT | Risk Ratio | Risk Ratio |
|-------------------|--------------|-----|------------|------------|
| Events | Total | Events | Total | Weight | M-H | Random | 95% CI | M-H | Random | 95% CI |
| 1.1.1 0-3 months (Median 1.5 months) | | | | | | | | | |
| Bonevski, 2021 | 8 | 34 | 12 | 29 | 11.0% | 0.57 [0.27, 1.20] | 0.57 [0.27, 1.20] |
| Bullen, 2014 | 67 | 289 | 47 | 295 | 26.2% | 1.46 [1.04, 2.04] | 1.46 [1.04, 2.04] |
| Hajek, 2019 | 192 | 438 | 134 | 446 | 35.2% | 1.46 [1.22, 1.74] | 1.46 [1.22, 1.74] |
| Lee, 2018 | 5 | 20 | 1 | 10 | 2.0% | 2.50 [0.34, 18.63] | 2.50 [0.34, 18.63] |
| Lee, 2019 | 34 | 75 | 35 | 75 | 25.6% | 0.87 [0.69, 1.37] | 0.87 [0.69, 1.37] |
| Subtotal (95% CI) | 856 | 855 | 100.0% | 1.29 [0.99, 1.69] | 1.29 [0.99, 1.69] |
| Total events | 306 | 229 | | | | | | |
| Heterogeneity: Tau² = 0.05; Chisquare = 9.88, df = 4 (P = 0.04); I² = 60% |
| Test for overall effect: Z = 1.21 (P = 0.22) |

1.1.2 3-6 months (Median 4.5 months) | | | | | | | | | |
| Bonevski, 2021 | 9 | 25 | 10 | 25 | 22.9% | 0.90 [0.44, 1.83] | 0.90 [0.44, 1.83] |
| Bullen, 2014 | 38 | 289 | 27 | 295 | 41.5% | 1.44 [0.90, 2.29] | 1.44 [0.90, 2.29] |
| Lee, 2018 | 5 | 20 | 1 | 10 | 3.5% | 2.50 [0.34, 18.63] | 2.50 [0.34, 18.63] |
| Lee, 2019 | 16 | 75 | 21 | 75 | 32.1% | 0.76 [0.43, 1.34] | 0.76 [0.43, 1.34] |
| Subtotal (95% CI) | 409 | 405 | 100.0% | 1.07 [0.73, 1.57] | 1.07 [0.73, 1.57] |
| Total events | 68 | 59 | | | | | | |
| Heterogeneity: Tau² = 0.04; Chisquare = 3.88, df = 3 (P = 0.28); I² = 23% |
| Test for overall effect: Z = 0.36 (P = 0.72) |

1.1.3 ≥6 months | | | | | | | | | |
| Bonevski, 2014 | 21 | 289 | 17 | 295 | 25.1% | 1.26 [0.68, 2.34] | 1.26 [0.68, 2.34] |
| Hajek, 2019 | 79 | 438 | 44 | 446 | 74.9% | 1.83 [1.30, 2.58] | 1.83 [1.30, 2.58] |
| Subtotal (95% CI) | 727 | 741 | 100.0% | 1.67 [1.21, 2.28] | 1.67 [1.21, 2.28] |
| Total events | 100 | 91 | | | | | | |
| Heterogeneity: Tau² = 0.00; Chisquare = 1.06, df = 1 (P = 0.30); I² = 6% |
| Test for overall effect: Z = 3.17 (P = 0.002) |
Figure 4. Subgroup analyses by follow-up duration in 7-day point abstinence rate in participants receiving e-cigarettes versus NRT

Subjects with any adverse events: when one participant has two or more adverse events, we counted it as 1.

Table 5. Adverse events in participants who received e-cigarettes versus NRT

Subjects with any adverse events: when one participant has two or more adverse events, we counted it as 1.
DISCUSSION

We found low certainty of evidence about e-cigarettes versus NRT was associated with a higher continuous abstinence rate and 7-day point abstinence rate at ≥6 months follow-up. However, the benefits of e-cigarettes in terms of continuous abstinence were not statistically significant at <6 months follow-up, as well as in 7-day point abstinence rate. We did not observe a significant difference in adverse events outcomes other than throat irritation.

We found interesting findings that both e-cigarettes and NRT increased continuous smoking cessation rate at ≥6 months (14% vs 8%), 3–6 months (17% vs 15%), and at <3 months (36% vs 27%), while along with the longer duration, the continuous smoking cessation
rate decreased in both groups, but more significantly in the NRT group (27% to 8%); based on that, it might imply that the e-cigarettes may be more superior to NRT in long-term smoking cessation.

This review showed the very low certainty that e-cigarette was associated with higher risk of adverse events. The results may be unreliable due to potential dual use of e-cigarettes with conventional cigarettes. Research showed that dual use of e-cigarettes and combusted tobacco could lead to more adverse health effects than the use of either one alone; and perhaps it was the biggest risk of using e-cigarettes to treat tobacco dependence40,41.

Our findings are consistent with the results from the study of Grabovac et al.42, a systematic review including 3 RCTs24,25,38 involving 1498 participants, which concluded the e-cigarettes were more effective than NRT in smoking cessation (RR=1.69; 95% CI: 1.25–2.27). Our study included an additional two RCTs23,39 instead of addressing the surrogate outcomes and we focused on the patient important outcomes including continuous abstinence rate and 7-day point abstinence rate. The former has the advantage of being more stable over time and across studies than point prevalence rates. Advantages of the point prevalence rate are that it has the potential to be validated biochemically and it can also be viewed as being sensitive to the early effects of an intervention, such as attempts to quit that are not maintained30.

There also exists another review conducted by Hartmann et al.26, which included 4 RCTs (1924 participants) in e-cigarettes versus NRT (but one of which was an abstract involving 216 participants), the quit rates were higher in e-cigarettes than NRT (RR=1.53; 95% CI: 1.21–1.93). Their study did not address the subgroup analysis of different follow-up duration, for which we showed that there might exist modifications in the continuous abstinence rate for different durations in our study. Further, our study included one more eligible trial and included 7-day point abstinence rate as another important outcome in the analysis.

Strengths and limitations

The strengths of our study include restricting inclusion of only RCTs, using the GRADE system to calculate absolute effects for each outcome and rate the certainty of evidence. Moreover, the subgroup analysis was conducted based on different follow-up durations to explore the impact of short-term, median-term and long-term follow-up duration on smoking cessation between e-cigarettes and NRT.

The present study also has limitations. First, the missing data ranged from 12% to 50% among the included studies, which can result in some bias. Second, the definitions of the continuous abstinence rate varied among studies, some were defined as no more than five cigarettes by self-report in the whole follow-up duration24,38, some were defined by biochemical indicators25, which might explain the partial heterogeneity of meta-analysis. Third, various dose and course of e-cigarette and NRT across studies may be a potential source of heterogeneity, the other source may be diversity of NRT regimens across studies, such as nicotine gum, patch, or inhalators. Finally, as no studies included pregnant women and considered the possible injury to vital fetal organs due to e-cigarettes43, our results do not apply to this special population.

Implications

Policymakers should balance the benefits and harms of e-cigarettes and NRT before they make decisions. Even though our findings showed that e-cigarettes appeared to be more effective than NRT in long-term duration, the harms between e-cigarettes and NRT are still uncertain, hence further studies are required to address this issue.

Further, policymakers may also need to refer to cost-effectiveness analysis to get more information before deciding whether the e-cigarettes are more cost-effective than NRT. One RCT estimated the lifetime incremental cost-effectiveness ratio of e-cigarettes to be £65 per quality-adjusted life-year (QALY) (85% probability below £20000/QALY), which indicated e-cigarettes as a highly cost-effective cessation aid compared with NRT44. Additionally, regulation of e-cigarettes should be strengthened since data for 2019 from Canada, England, and the US, show regular use (≥20 days in the last 30 days) among those aged 16–17, 17–18 and 18–19 years to be 5.7%, 2.7% and 6.7%45, respectively, and multiple international cohort studies have consistently confirmed a strong correlation between e-cigarette use among adolescents and young adults and subsequent cigarette use46,47.
CONCLUSIONS
Based on the limited low certainty evidence, e-cigarettes appear to be superior to NRT in continuous abstinence rate and 7-day point abstinence rate at long-term duration. At short-term duration, we found no evidence that e-cigarettes compared to NRT increased <6 months continuous abstinence rate and 7-day point abstinence rate. The paucity of reliable research decreases the confidence in the results.

REFERENCES
1. World Health Organization. Tobacco. Accessed March 9, 2022. https://www.who.int/health-topics/tobacco#tab=tab_2
2. Jha P, Ramasundarahettige C, Landsman V, et al. 21st-century hazards of smoking and benefits of cessation in the United States. N Engl J Med. 2013;368(4):341-350. doi:10.1056/NEJMsas1211128
3. Toll BA, Rojewski AM, Duncan LR, et al. “Quitting smoking will benefit your health”: the evolution of clinician messaging to encourage tobacco cessation. Clin Cancer Res. 2014;20(2):301-309. doi:10.1158/1078-0432.CCR-13-2261
4. Sung B. E-cigarette Use and Smoking Cessation Among South Korean Adult Smokers: A Propensity Score-Matching Approach. Asia Pac J Public Health. 2018;30(4):332-341. doi:10.1177/1010539517740054
5. Brown R, Bauld L, de Lacy E, et al. A qualitative study of e-cigarette emergence and the potential for renormalisation of smoking in UK youth. Int J Drug Policy. 2020;75:102598. doi:10.1016/j.drugpo.2019.11.006
6. Sapru S, Vardhan M, Li Q, Guo Y, Li X, Saxena D. E-cigarettes use in the United States: reasons for use, perceptions, and effects on health. BMC Public Health. 2020;20(1):1518. doi:10.1186/s12889-020-09572-x
7. Rahman MA, Hann N, Wilson A, Worrall-Carter L. Electronic cigarettes: patterns of use, health effects, use in smoking cessation and regulatory issues. Tob Induc Dis. 2014;12(1):21. doi:10.1186/1617-9625-12-21
8. Sutherland G. Smoking: can we really make a difference? Heart. 2003;89 Suppl 2(Suppl 2):ii25-7; discussion ii35-ii27. doi:10.1136/heart.89.suppl_2.i25
9. Ferguson SG, Shiffman S, Gitchell JG. Nicotine replacement therapies: patient safety and persistence. Patient Relat Outcome Meas. 2011;2:111-117. doi:10.2147/PROM.S11545
10. Centers for Disease Control and Prevention. About Electronic Cigarettes (E-Cigarettes). Accessed March 9, 2022. https://www.cdc.gov/tobacco/basic_information/e-cigarettes/about-e-cigarettes.html
11. Brown DE. E-cigarettes Spark Nicotine Replacement Therapy Mutiny. Newswire. July 29, 2015. Accessed March 9, 2022. https://newswire.net/newsroom/pr/00089726-e-cigarettes-spark-nicotine-replacement-therapy-mutiny.html
12. Gravely S, Cummings KM, Hammond D, et al. The Association of E-cigarette Flavors With Satisfaction, Enjoyment, and Trying to Quit or Stay Abstinent From Smoking Among Regular Adult Vapers From Canada and the United States: Findings From the 2018 ITC Four Country Smoking and Vaping Survey. Nicotine Tob Res. 2020;22(10):1831-1841. doi:10.1093/ntr/ntaa095
13. Gualano MR, Passi S, Bert F, La Torre G, Scialoli G, Siliquini R. Electronic cigarettes: assessing the efficacy and the adverse effects through a systematic review of published studies. J Public Health (Oxf). 2015;37(3):488-497. doi:10.1093/pubmed/fdu055
14. Centers for Disease Control and Prevention. Outbreak of Lung Injury Associated with the Use of E-Cigarette, or Vaping, Products. Updated February 25, 2020. Accessed March 9, 2022. https://www.cdc.gov/tobacco/basic_information/e-cigarettes/severe-lung-disease.html
15. Mayer B, Nitschmann S. Lung injury induced by e-cigarettes. Lungenschäden durch E-Zigaretten. Internist (Berl). 2020;61(11):1204-1207. doi:10.1007/s00108-020-00879-w
16. Rohde JA, Noar SM, Mendel JR, et al. E-Cigarette Health Harm Awareness and Discouragement: Implications for Health Communication. Nicotine Tob Res. 2020;22(7):1131-1138. doi:10.1093/ntr/ntz194
17. Herman M, Tarran R. E-cigarettes, nicotine, the lung and the brain: multi-level cascading pathophysiology. J Physiol. 2020;598(22):5063-5071. doi:10.1113/JP278388
18. U.S. National Center for Chronic Disease Prevention and Health Promotion - Office on Smoking and Health. E-Cigarette Use Among Youth and Young Adults: A Report of the Surgeon General. U.S. Centers for Disease Control and Prevention; 2016. Accessed March 9, 2022. https://www.ncbi.nlm.nih.gov/books/NBK538680/
19. Little Caldwell A. E-Cigarette Use During Pregnancy & Breastfeeding FAQs. Updated September 9, 2019. Accessed March 9, 2022. https://www.healthchildren.org/English/ages-stages/prenatal/Pages/E-Cigarette-Use-During-Pregnancy-Breastfeeding.aspx
20. Brown J, Beard E, Kotz D, Michie S, West R. Real-world effectiveness of e-cigarettes when used to aid smoking cessation: a cross-sectional population study. Addiction. 2014;109(9):1531-1540. doi:10.1111/add.12623
21. Cox S, Dawkins L, Doshi J, Cameron J. Effects of e-cigarettes versus nicotine replacement therapy on short-term smoking abstinence when delivered at a community pharmacy. Addict Behav Rep. 2019;10:100202. doi:10.1016/j.jabrep.2019.100202
22. Barbeau AM, Burda J, Siegel M. Perceived efficacy of e-cigarettes versus nicotine replacement therapy among successful e-cigarette users: a qualitative approach. Addict Sci Clin Pract. 2013;8(1):5. doi:10.1186/1940-0640-8-5
23. Lee SH, Ahn SH, Cheong YS. Effect of Electronic Tobacco Induced Diseases
Cigarettes on Smoking Reduction and Cessation in Korean Male Smokers: A Randomized Controlled Study. J Am Board Fam Med. 2019;32(4):567-574. doi:10.3122/jabfm.2019.04.180384

24. Bullen C, Howe C, Laugesen M, et al. Electronic cigarettes for smoking cessation: a randomised controlled trial. Lancet. 2013;382(9905):1629-1637. doi:10.1016/S0140-6736(13)61842-5

25. Lee SM, Tenney R, Wallace AW, Arjomandi M. E-cigarettes versus nicotine patches for perioperative smoking cessation: a pilot randomized trial. PeerJ. 2018;6:e5609. doi:10.7717/peerj.5609

26. Hartmann-Bouye J, McRobbie H, Butler AR, et al. Electronic cigarettes for smoking cessation. Cochrane Database Syst Rev. 2021;9(9):CD010216. doi:10.1002/14651858.CD010216.pub6

27. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. doi:10.1371/journal.pmed.1000097

28. Tian J, Zhang J, Ge L, Yang K, Song F. The methodological and reporting quality of systematic reviews from China and the USA are similar. J Clin Epidemiol. 2017;85:50-58. doi:10.1016/j.jclinepi.2016.12.004

29. Wang X, Chen Y, Yao L, et al. Reporting of declarations and conflicts of interest in WHO guidelines can be further improved. J Clin Epidemiol. 2018;98:1-8. doi:10.1016/j.jclinepi.2017.12.021

30. Velicer WF, Prochaska JO, Rossi JS, Snow MG. Assessing outcome in smoking cessation studies. Psychol Bull. 1992;111(1):23-41. doi:10.1037/0033-2909.111.1.23

31. Lu T, Lu C, Li H, et al. The reporting quality and risk of bias of randomized controlled trials of acupuncture for migraine: Methodological study based on STRICTA and RoB 2.0. Complement Ther Med. 2020;52:102433. doi:10.1016/j.ctim.2020.102433

32. Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. doi:10.1136/bmj.l4898

33. Brozek JL, Akl EA, Alonso-Coello P, et al. Grading quality of evidence and strength of recommendations in clinical practice guidelines. Part 1 of 3. An overview of the GRADE approach and grading quality of evidence about interventions. Allergy. 2009;64(5):669-677. doi:10.1111/j.1398-9995.2009.01973.x

34. Yang K, Chen Y, Li Y, Schünemann HJ; Members of the Lanzhou International Guideline Symposium. Editorial: can China master the guideline challenge? Health Res Policy Syst. 2013;11:1. doi:10.1186/1478-4505-11-1

35. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924-926. doi:10.1136/bmj.39489.470347.AD

36. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557-560. doi:10.1136/bmj.327.7414.557

37. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629-634. doi:10.1136/bmj.315.7109.629

38. Hajek P, Phillips-Waller A, Pruzl J, et al. A Randomized Trial of E-Cigarettes versus Nicotine-Replacement Therapy. N Engl J Med. 2019;380(7):629-637. doi:10.1056/NEJMoa1808779

39. Bonevski B, Manning V, Wynne O, et al. QuitNic: A Pilot Randomized Controlled Trial Comparing Nicotine Vaping Products With Nicotine Replacement Therapy for Smoking Cessation Following Residential Detoxification. Nicotine Tob Res. 2021;23(3):462-470. doi:10.1093/nttr/ntaa143

40. Wang JB, Olgin JE, Nah G, et al. Cigarette and e-cigarette dual use and risk of cardiopulmonary symptoms in the Health eHeart Study. PLoS One. 2018;13(7):e0198681. doi:10.1371/journal.pone.0198681

41. Goniewicz ML, Smith DM, Edwards KC, et al. Comparison of Nicotine and Toxicant Exposure in Users of Electronic Cigarettes and Combustible Cigarettes. JAMA Netw Open. 2018;1(8):e185937. doi:10.1001/jamanetworkopen.2018.5937

42. Grabovac I, Oberndorfer M, Fischer J, Wiesinger W, Haider S, Dorner TE. Effectiveness of Electronic Cigarettes in Smoking Cessation: A Systematic Review and Meta-analysis. Nicotine Tob Res. 2021;23(4):625-634. doi:10.1093/nttr/ntaa181

43. Centers for Disease Control and Prevention. E-Cigarettes and Pregnancy. Updated February 25, 2019. Accessed March 9, 2022. https://www.cdc.gov/reproductivehealth/pregnancy.htm

44. Li J, Hajek P, Pesola F, et al. Cost-effectiveness of e-cigarettes compared with nicotine replacement therapy in stop smoking services in England (TEC study): a randomized controlled trial. Addiction. 2020;115(3):507-517. doi:10.1111/add.14829

45. Hammond D, Rynard VL, Reid JL. Changes in Prevalence of Vaping Among Youths in the United States, Canada, and England from 2017 to 2019. JAMA Pediatr. 2020;174(8):797-800. doi:10.1001/jamapediatrics.2020.0901

46. O’Brien D, Long J, Quigley J, Lee C, McCarthy A, Kavanagh P. Association between electronic cigarette use and tobacco cigarette smoking initiation in adolescents: a systematic review and meta-analysis. BMC Public Health. 2021;21(1):954. doi:10.1186/s12889-021-10935-1

47. East K, Hitchman SC, Bakolis I, et al. The Association Between Smoking and Electronic Cigarette Use in a Cohort of Young People. J Adolesc Health. 2018;62(5):539-547. doi:10.1016/j.jadohealth.2017.11.301
CONFLICTS OF INTEREST
The authors have each completed and submitted an ICMJE form for disclosure of potential conflicts of interest. The authors declare that they have no competing interests, financial or otherwise, related to the current work. All the authors report that since the initial planning of the work that this study was supported by the Major Project of the National Social Science Fund of China: Research on the Theoretical System, International Experience, and Chinese Path of Evidence-based Social Science (No. 19ZDA14).

FUNDING
This research is supported by the Major Project of the National Social Science Fund of China: Research on the Theoretical System, International Experience, and Chinese Path of Evidence-based Social Science (No. 19ZDA14). The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

ETHICAL APPROVAL AND INFORMED CONSENT
Ethical approval and informed consent were not required for this study.

DATA AVAILABILITY
The data supporting this research can be found in the Supplementary file.

AUTHORS’ CONTRIBUTIONS
JL, XH and LY had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Concept and design: JL, XH, LY and KY. Acquisition, analysis, or interpretation of data: JL, JF, XH and MMA. Drafting of the manuscript: JL. Critical revision of the manuscript for important intellectual content: JL, LY, XH and MMA. Statistical analysis: JL, XH and LY. Obtained funding: LY and KY. Administrative, technical, or material support: JL. Supervision: LY and KY.

PROVENANCE AND PEER REVIEW
Not commissioned; externally peer reviewed.